Baseline characteristics of 448 lupus patients with low-grade disease activity
| Baseline characteristics | Items | n (%)/mean±SD |
| Demographics | Gender (F%) | 409 (91.3) |
| Age (year) | 34.4±12.6 | |
| SLE duration (year) | 7.0±6.3 | |
| Autoantibodies and complements | Anti-Sm, n (%) | 99 (22.1) |
| Ant-U1RNP, n (%) | 175 (39.2) | |
| Anti-SSA, n (%) | 263 (58.7) | |
| Anti-SSB, n (%) | 63 (14.1) | |
| Anti-ribosomal-P, n (%) | 89 (19.9) | |
| aPL, n (%) | 74 (16.5) | |
| Anti-ds-DNA+, n (%) | 252 (56.3) | |
| Low complement 3, n (%) | 246 (54.9) | |
| Low complement 4, n (%) | 77 (17.2) | |
| Evaluation | SLEDAI | 2.47±2.00 |
| Baseline attainment of LDAS/remission | LDAS−, n (%) | 238 (53.1) |
| LDAS+/remission−, n (%) | 86 (19.2) | |
| Remission +, n (%) | 124 (27.7) | |
| Baseline therapy | Prednisone (mg/day) | 8.59±4.98 |
| HCQ, n (%) | 399 (89.1) | |
| IS, n (%) | 267 (59.6) |
aPL, antiphospholipid antibodies; LDAS, low disease activity status; HCQ, hydroxychloroquine; IS, immunosuppressive agents.